Iovance Biotherapeutics, Inc. (IOVA)
IOVANASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$8.22
+0.1800 (+2.24%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $3.78bn
- P/E
- –
- EPS, last 4 quarters
- $-0.5300
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.08 to $15.37
- Average volume
- 15.91m
- Previous close
- $8.04
Analysts
10 coveringBuy8 buy, 2 hold, 0 sell
Targets a year out average $14.80, +80.0% from here
Earnings
next estimate $-0.0900Next report
Dec 2025
+18.2%
Mar 2026
0.0%
Jun 2026
+35.3%
Sep 2026
+44.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $86.77m | $71.43m | $99.31m | $121.47m |
| Gross profit | $43.66m | $28.93m | $55.72m | $73.44m |
| Operating income | -$73.46m | -$81.04m | -$51.91m | -$23.97m |
| Net income | -$71.90m | -$79.05m | -$47.31m | -$22.27m |
Last four quarters: revenue $378.98m, margin -58.2%, free cash flow -$216.06m
News
8 latest- IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D CostsZacks · 4 days ago
- IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline ProgressZacks · 4 days ago
- Iovance (IOVA) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- Iovance Biotherapeutics Q3 Earnings Call HighlightsMarketBeat · 4 days ago
- Iovance Biotherapeutics, Inc. Reports Record Third Quarter 2026 Revenue of ~$122MFintel · 4 days ago
- Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedZacks · 6 days ago
- NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook RaisedZacks · 6 days ago
The company
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi (lifileucel) is the first FDA -approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S .-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- iovance.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.